RBC Capital Analyst Reaffirms Confidence in BioCryst Pharma with Outperform Rating and 10 Price Target
September 25, 2023 - In a noteworthy turn of events, esteemed RBC Capital analyst, Brian Abrahams, has once again expressed ...
Tag: BCRX
RBC Capital Upgrades BioCryst Pharmas Status and Raises Price Target
On September 18, 2023, an optimistic development emerged for BioCryst Pharma (NASDAQ:BCRX) as RBC Capital analyst Brian Abrahams upgraded the ...
Innovative Medication for Hereditary Angioedema Receives Positive Recommendation for Reimbursement in Quebec
On September 18, 2023, the Institut National D'excellence En Santé Et Services Sociaux (INESSS) made a significant announcement regarding BioCryst ...
Berkshire Hathaway Inc Shows Confidence in Diageo plc with Notable Investment
On September 12, 2023, Berkshire Hathaway Inc made a notable investment by purchasing a new stake in Diageo plc (NYSE:DEO) ...
Avoro Capital Advisors LLC Increases Holdings in BioCryst Pharmaceuticals, Reflecting Confidence in Biotech’s Potential for Growth
Avoro Capital Advisors LLC, an investment management firm, recently disclosed in its most recent filing with the Securities and Exchange ...
Russell Investments Group Ltd. Increases Stake in BioCryst Pharmaceuticals, Inc.; Company Reports Strong Earnings and Insider Selling
Russell Investments Group Ltd. has reportedly increased its stake in BioCryst Pharmaceuticals, Inc. during the first quarter of this year, ...
ExodusPoint Capital Management Increases Stake in BioCryst Pharmaceuticals, Showing Confidence in Biotech Firm’s Potential
ExodusPoint Capital Management LP, a prominent institutional investor, has significantly increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the ...
BioCryst Pharmaceuticals: A Promising Investment Opportunity Backed by Landscape Capital Management
Landscape Capital Management L.L.C., a prominent investment firm, has recently acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). According ...
Pictet Asset Management SA Increases Position in BioCryst Pharmaceuticals, Inc. by 6.3%
Pictet Asset Management SA, a prominent institutional investor, has increased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 6.3% during ...
BioCryst Pharmaceuticals Receives Hold Rating from StockNews.com, Reports Mixed Financial Results
BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotechnology company, recently received coverage from equities research analysts at StockNews.com. The analysts issued a "hold" ...